Respiratory Diseases and their Treatments that will Soon Come Off Patent

The chronic obstructive pulmonary disease (COPD) space across the eight major markets (US, France, Germany, Italy, Spain, the UK, Japan, and Australia,) is set to rise from $9.9 billion in 2015 to around $14.1 billion by 2025 according to GlobalData. The worldwide market for Asthma and COPD Drugs is expected to reach $7.46 Billion US in 2023, from $5.2 Billion US in 2017.

Our Infographic highlights Respiratory Diseases and the drugs that treat them that are coming off patent. Learn how Navitas Life Sciences can help you get to market with your replacements faster.



© 2019 Navitas Life Sciences | Privacy Policy